Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Dermatology

Free Subscription Articles published in Cancer Retrieve available abstracts of 118 articles: HTML format

Single Articles

November 2025
1. BARBER LE, Maliniak ML, Miller-Kleinhenz JM, Moubadder L, et al
   Understanding the role of neighborhood deprivation in racial disparities in triple-negative breast cancer.
   Cancer. 2025;131:e70138.
   PubMed     Abstract available
   
   
   October 2025
2. GIAQUINTO AN, Freedman RA, Newman LA, Jemal A, et al
   Lobular breast cancer statistics, 2025.
   Cancer. 2025;131:e70061.
   PubMed     Abstract available
   
   
   
3. BOWER JE, Radin A, Ganz PA, Irwin MR, et al
   Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination.
   Cancer. 2025;131:e70038.
   PubMed     Abstract available
   
   
   
4. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
   Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
   Cancer. 2025;131 Suppl 2.
   PubMed     Abstract available
   
   
   
5. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
   Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
   Cancer. 2025;131:e70073.
   PubMed     Abstract available
   
   
   
6. RIBI K, Cole BF, Fleming GF, Walley BA, et al
   Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
   Cancer. 2025;131:e70094.
   PubMed     Abstract available
   
   
   
7. COLAES R, Schroyen G, Radwan A, Gavrila Laic RA, et al
   Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition.
   Cancer. 2025;131:e70095.
   PubMed     Abstract available
   
   
   
8. SHAFFER KM, Daniel KE, Wiseman KP, Ritterband LM, et al
   Prospective associations between sleep quality and sexual satisfaction in distressed breast cancer survivors: Secondary analysis from the Apps Reaching Cancer Survivors randomized trial.
   Cancer. 2025;131:e70093.
   PubMed     Abstract available
   
   
   September 2025
9. ROOHANI S, Griffin AM, Liu ZA, Catton CN, et al
   Preoperative intensity-modulated radiation therapy in lower extremity soft tissue sarcomas with and without dose avoidance of uninvolved skin/subcutaneous tissue.
   Cancer. 2025;131:e70049.
   PubMed     Abstract available
   
   
   
10. CHEN M, Lin Z, Chen X, Zhang J, et al
    Feasibility and accuracy of targeted axillary dissection by carbon tattooing in biopsy-proven node-positive breast cancer: A prospective study.
    Cancer. 2025;131:e70047.
    PubMed     Abstract available
    
    
    August 2025
11. MILHEM MM, Zakharia Y, Davar D, Buchbinder EI, et al
    Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
    Cancer. 2025;131:e70022.
    PubMed     Abstract available
    
    
    July 2025
12. FONTVIEILLE E, Jansana A, Peruchet-Noray L, Cordova R, et al
    Body mass index and breast cancer risk among postmenopausal women with and without cardiometabolic diseases: Findings from two prospective cohort studies in Europe.
    Cancer. 2025;131:e35911.
    PubMed     Abstract available
    
    
    
13. MENZIES AM, Salman P, Frontera OA, Pook D, et al
    Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
    Cancer. 2025;131:e35962.
    PubMed     Abstract available
    
    
    
14. KIM Y, Doma V, Cakir U, Kuras M, et al
    Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies.
    Cancer. 2025;131:e35897.
    PubMed     Abstract available
    
    
    June 2025
15. FUMAGALLI IA, Warner ET, Llanos AAM, Quesenberry CP, et al
    Racial and ethnic variation in body composition and prognosis of nonmetastatic breast cancer.
    Cancer. 2025;131:e35926.
    PubMed     Abstract available
    
    
    
16. WANIS KN, Mitchell MP, Giordano SH, Litton JK, et al
    Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers.
    Cancer. 2025;131:e35910.
    PubMed     Abstract available
    
    
    
17. AUBUCHON KE, Galvan CJC, Duron Y, Sampayo I, et al
    Randomized trial of a community-based, culturally tailored intervention: High engagement among Latina breast cancer survivors.
    Cancer. 2025;131:e35842.
    PubMed     Abstract available
    
    
    
18. TRINCONI CUNHA M, Wallace N, Porceddu S, Ferrarotto R, et al
    Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.
    Cancer. 2025;131:e35920.
    PubMed     Abstract available
    
    
    
19. NIERENGARTEN MB
    New standard of care for patients with asymptomatic brain metastases from melanoma.
    Cancer. 2025;131:e35885.
    PubMed    
    
    
    May 2025
20. LEE MS, Thomas SM, Louie AD, Rosenberger LH, et al
    Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer.
    Cancer. 2025;131:e35891.
    PubMed     Abstract available
    
    
    
21. ZHANG H, Charlton BM, Schnarrs PW, Trentham-Dietz A, et al
    Mammography screening and risk factor prevalence by sexual identity: A comparison of two national surveys.
    Cancer. 2025;131:e35852.
    PubMed     Abstract available
    
    
    
22. YEN TWF, Nattinger AB, Bickell NA, Schymura MJ, et al
    Does regionalization of initial breast cancer care delay time to surgery?
    Cancer. 2025;131:e35895.
    PubMed     Abstract available
    
    
    
23. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    PubMed     Abstract available
    
    
    
24. ZOPE M, Sullivan R, Gutnik L
    Fragmented care and misaligned incentives of stakeholders in breast cancer care for the uninsured in the United States.
    Cancer. 2025;131:e35878.
    PubMed     Abstract available
    
    
    
25. PEARCE A, Carter S, Frazer HM, Houssami N, et al
    Implementing artificial intelligence in breast cancer screening: Women's preferences.
    Cancer. 2025;131:e35859.
    PubMed     Abstract available
    
    
    
26. SIMON LH, Saviers-Steiger C, Dunston ER, Galyean P, et al
    Feasibility and acceptability of the Comprehensive Oncology Rehabilitation and Exercise (CORE) clinical workflow algorithm in patients with newly diagnosed stage I-III breast cancer who undergo surgery as first-line treatment.
    Cancer. 2025;131:e35798.
    PubMed     Abstract available
    
    
    
27. CHEN MF, Postow MA
    Top advances of the year: Neoadjuvant immunotherapy in melanoma.
    Cancer. 2025;131:e35877.
    PubMed    
    
    
    
28. NIERENGARTEN MB
    Two-fold increased risk of melanoma in childhood cancer survivors.
    Cancer. 2025;131:e35828.
    PubMed    
    
    
    April 2025
29. ZEINOMAR N, Perlstein M, Qin B, Iyer HS, et al
    Associations between experiences of discrimination and quality of life in Black breast cancer survivors.
    Cancer. 2025;131:e35836.
    PubMed     Abstract available
    
    
    
30. PALESH O, Braun SE, Truong T, Hong S, et al
    Natural trajectory subclasses of cognitive impairment in breast cancer patients experiencing insomnia.
    Cancer. 2025;131:e35816.
    PubMed     Abstract available
    
    
    
31. GRAFF SL, Tolaney SM, Hart LL, Razavi P, et al
    Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer.
    Cancer. 2025;131:e35817.
    PubMed     Abstract available
    
    
    March 2025
32. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    PubMed     Abstract available
    
    
    
33. PATEL RB, Sheng T, Diniz MA, Sparano JA, et al
    Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis.
    Cancer. 2025;131:e35771.
    PubMed     Abstract available
    
    
    
34. NIERENGARTEN MB
    Immune checkpoint inhibitors increase the risk of psoriasis.
    Cancer. 2025;131:e35753.
    PubMed    
    
    
    February 2025
35. MAZOR M, Lin JJ, Smith C, Rosa WE, et al
    Community-engaged adaptation of ACCESS: A navigator-led early palliative care intervention for Black and Latina women with advanced breast cancer.
    Cancer. 2025;131:e35745.
    PubMed     Abstract available
    
    
    
36. BAEKER BISPO J, Jemal A, Islami F
    Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
    Cancer. 2025;131:e35724.
    PubMed     Abstract available
    
    
    
37. WAKS AG, Tarantino P, Chen EL, Freedman RA, et al
    Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010-2019.
    Cancer. 2025;131:e35729.
    PubMed     Abstract available
    
    
    
38. MARCOTTE LM, Khor S, Reddy A, Morenz A, et al
    An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system.
    Cancer. 2025;131:e35734.
    PubMed     Abstract available
    
    
    January 2025
39. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    PubMed     Abstract available
    
    
    
40. RAJABIUN S, Cabral HJ, Chen CA, Lloyd-Travaglini C, et al
    Cost and activity analysis for a citywide patient navigation intervention to engage underserved patients in breast cancer treatment: Findings from the Translating Research Into Practice study.
    Cancer. 2025;131:e35671.
    PubMed     Abstract available
    
    
    
41. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
    Cancer. 2025;131:e35664.
    PubMed     Abstract available
    
    
    
42. BONTEMPS-JONES JE, McCullough LE, Kirkland EG, Teras LR, et al
    Beyond Tuskegee: A contemporary qualitative assessment of barriers to research participation among Black women.
    Cancer. 2025;131:e35648.
    PubMed     Abstract available
    
    
    
43. NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al
    Effects of a culturally tailored patient navigation program on unmet supportive care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
    Cancer. 2025;131:e35626.
    PubMed     Abstract available
    
    
    
44. SHIN DS, Ryu JM, Lee SK, Yu J, et al
    Nonsentinel lymph node metastases in cases of micrometastasis detected by sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Cancer. 2025;131:e35567.
    PubMed     Abstract available
    
    
    
45. TAN NQP, Ma GX, Maxwell AE, Brown RL, et al
    The impact of a small-group mammography video discussion on promoting screening uptake among nonadherent Chinese American immigrant women: A randomized controlled trial.
    Cancer. 2025;131:e35524.
    PubMed     Abstract available
    
    
    
46. WINER LK, Akumuo R, Fredette JD, Deng M, et al
    Current patterns of care and outcomes for dermatofibrosarcoma protuberans: An international multi-institutional collaborative.
    Cancer. 2025;131:e35468.
    PubMed     Abstract available
    
    
    December 2024
47. LIU KX, Shin KY, Thakuria M, Schoenfeld JD, et al
    Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence.
    Cancer. 2024;130:4267-4275.
    PubMed     Abstract available
    
    
    
48. DANIELSEN JT, Zachariae R, Schmidt H, Kallehauge JF, et al
    Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35683.
    PubMed     Abstract available
    
    
    
49. LE BRUN IC, Dalle S, Mortier L, Dereure O, et al
    Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.
    Cancer. 2024 Dec 8. doi: 10.1002/cncr.35679.
    PubMed     Abstract available
    
    
    
50. REESE JB, Lepore SJ, Sorice KA, Zimmaro LA, et al
    Efficacy of a couple-based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial.
    Cancer. 2024 Dec 8. doi: 10.1002/cncr.35685.
    PubMed     Abstract available
    
    
    November 2024
51. YAROSH RA, Nichols HB, Wang Q, Hirschey R, et al
    Patient-reported persistent lymphedema and peripheral neuropathy among long-term breast cancer survivors in the Carolina Breast Cancer Study.
    Cancer. 2024 Nov 17. doi: 10.1002/cncr.35650.
    PubMed     Abstract available
    
    
    
52. DESAI P, Zhou Y, Grenet J, Handelman SK, et al
    Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.
    Cancer. 2024;130:3879-3887.
    PubMed     Abstract available
    
    
    
53. DEPALO DK, Dugan MM, Naqvi SMH, Ollila DW, et al
    A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35636.
    PubMed     Abstract available
    
    
    October 2024
54. MUSLUMANOGLU M, Cabioglu N, Igci A, Karanlik H, et al
    Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35610.
    PubMed     Abstract available
    
    
    
55. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    PubMed     Abstract available
    
    
    
56. BRUNET J, Sharma S, Zadravec K, Taljaard M, et al
    Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE): A randomized controlled trial.
    Cancer. 2024 Oct 21. doi: 10.1002/cncr.35540.
    PubMed     Abstract available
    
    
    
57. GARG N, Thorat MA
    A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition of the research question and a robust study design.
    Cancer. 2024;130:3549-3550.
    PubMed    
    
    
    
58. ZHENG QJ, Xu L, Fan ZQ
    Reply to "A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition of the research question and a robust study design".
    Cancer. 2024;130:3551-3552.
    PubMed    
    
    
    
59. TIN TIN S, Smith-Byrne K, Ferrari P, Rinaldi S, et al
    Alcohol intake and endogenous sex hormones in women: Meta-analysis of cohort studies and Mendelian randomization.
    Cancer. 2024;130:3375-3386.
    PubMed     Abstract available
    
    
    
60. SHI KS, Han X, Star J, Zhao J, et al
    Association of health insurance coverage disruptions and breast and colorectal cancer screening.
    Cancer. 2024 Oct 1. doi: 10.1002/cncr.35584.
    PubMed     Abstract available
    
    
    September 2024
61. LAO CD, Moon J, Ma VT, Fruehauf JP, et al
    Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587.
    PubMed     Abstract available
    
    
    
62. SELLA T, Sorouri K, Rosenberg SM, Loucks M, et al
    Breastfeeding experiences among young breast cancer survivors: A survey study.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35585.
    PubMed     Abstract available
    
    
    
63. IYENGAR NM, Scott JM, Lee J, Lavery JA, et al
    Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial.
    Cancer. 2024 Sep 22. doi: 10.1002/cncr.35575.
    PubMed     Abstract available
    
    
    
64. WANG X, Shang Y, Zhang J, Liu J, et al
    Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study.
    Cancer. 2024 Sep 22. doi: 10.1002/cncr.35581.
    PubMed     Abstract available
    
    
    
65. ELSHAFIE S, Trivedi R, Villa-Zapata LA, Tackett RL, et al
    Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis.
    Cancer. 2024 Sep 5. doi: 10.1002/cncr.35550.
    PubMed     Abstract available
    
    
    
66. LI R, Hua M, Li J, Chen W, et al
    The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis.
    Cancer. 2024;130:2968-2977.
    PubMed     Abstract available
    
    
    
67. XU C, Chen Z, Xia Y, Shi Y, et al
    Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.
    Cancer. 2024;130.
    PubMed     Abstract available
    
    
    August 2024
68. PARK KU, Lipsitz S, Dominici LS, Lynce F, et al
    Generative artificial intelligence as a source of breast cancer information for patients: Proceed with caution.
    Cancer. 2024 Aug 30. doi: 10.1002/cncr.35521.
    PubMed     Abstract available
    
    
    
69. PLICHTA JK, Thomas SM, Chanenchuk TC, Chan K, et al
    Comparison of incident breast cancer cases in the largest national US tumor registries.
    Cancer. 2024 Aug 18. doi: 10.1002/cncr.35525.
    PubMed     Abstract available
    
    
    
70. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    PubMed     Abstract available
    
    
    
71. NIERENGARTEN MB
    Inequities in breast cancer from prevention through supportive care.
    Cancer. 2024;130:2570.
    PubMed    
    
    
    
72. MILLER DM, Shalhout SZ, Wright KM, Miller MA, et al
    The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study.
    Cancer. 2024;130:2670-2682.
    PubMed     Abstract available
    
    
    July 2024
73. ROZEMAN EA, Luke JJ
    The emergence of neoadjuvant immune-over BRAF therapy in melanoma.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35490.
    PubMed    
    
    
    
74. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    PubMed     Abstract available
    
    
    June 2024
75. REINER AS, Knight JA, John EM, Lynch CF, et al
    Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window.
    Cancer. 2024 Jun 28. doi: 10.1002/cncr.35459.
    PubMed     Abstract available
    
    
    
76. LU W, Giobbie-Hurder A, Tanasijevic A, Kassis SB, et al
    Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials.
    Cancer. 2024 Jun 24. doi: 10.1002/cncr.35374.
    PubMed     Abstract available
    
    
    
77. DENT S, Tumlinson R, Guha A, Moore H, et al
    Breast cancer risk reduction: Beyond pharmacologic intervention.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35442.
    PubMed    
    
    
    
78. CHUNG HC, Saada-Bouzid E, Longo F, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35387.
    PubMed     Abstract available
    
    
    
79. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    PubMed     Abstract available
    
    
    
80. CZARNECKA AM, Ostaszewski K, Blonski PJ, Szumera-Cieckiewicz A, et al
    Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Cancer. 2024 Jun 6. doi: 10.1002/cncr.35425.
    PubMed     Abstract available
    
    
    
81. SELMOUNI F, Bendahhou K, Sauvaget C, Abahssain H, et al
    Impact of CBE-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35419.
    PubMed     Abstract available
    
    
    May 2024
82. BELAU MH, Jung L, Maurer T, Obi N, et al
    Social relationships and their impact on health-related quality of life in a long-term breast cancer survivor cohort.
    Cancer. 2024 May 17. doi: 10.1002/cncr.35364.
    PubMed     Abstract available
    
    
    
83. SCHETTINI F, Blondeaux E, Molinelli C, Bas R, et al
    Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35323.
    PubMed     Abstract available
    
    
    
84. CHLEBOWSKI RT, Aragaki AK, Pan K, Simon MS, et al
    Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative.
    Cancer. 2024 May 13. doi: 10.1002/cncr.35318.
    PubMed     Abstract available
    
    
    
85. HOVHANNISYAN M, Zemankova P, Nehasil P, Matejkova K, et al
    Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35337.
    PubMed     Abstract available
    
    
    
86. GUO H, Malone KE, Heckbert SR, Li CI, et al
    Statin use and risks of breast cancer recurrence and mortality.
    Cancer. 2024 May 6. doi: 10.1002/cncr.35362.
    PubMed     Abstract available
    
    
    April 2024
87. KHATTAK MA, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354.
    PubMed    
    
    
    
88. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    PubMed    
    
    
    
89. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    PubMed    
    
    
    
90. BERNSTEIN-MOLHO R, Shhada NA, Laitman Y, Netzer I, et al
    Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed >/=50 years.
    Cancer. 2024 Apr 17. doi: 10.1002/cncr.35329.
    PubMed     Abstract available
    
    
    
91. VANNIER AGL, Dhungana A, Zhao F, Chen N, et al
    Validation of the RSClin risk calculator in the National Cancer Data Base.
    Cancer. 2024;130:1210-1220.
    PubMed     Abstract available
    
    
    
92. NIERENGARTEN MB
    Routine estradiol testing recommended for women at high risk of breast cancer.
    Cancer. 2024;130:1014.
    PubMed    
    
    
    
93. NIERENGARTEN MB
    Cardiotoxicity of breast cancer drugs requires additional monitoring.
    Cancer. 2024;130:1013-1014.
    PubMed    
    
    
    
94. DELEIRE T, Mitchell JM, De La Cruz L, Isaacs C, et al
    Nonclinical factors associated with the treatment of older women with newly diagnosed low-grade ductal carcinoma in situ.
    Cancer. 2024;130:1041-1051.
    PubMed     Abstract available
    
    
    March 2024
95. WANG X, O'Regan RM
    Breast cancer therapy in China: Introducing the Special Collection.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35288.
    PubMed    
    
    
    
96. NIERENGARTEN MB
    FDA approves capivasertib with fulvestrant for breast cancer.
    Cancer. 2024;130:835-836.
    PubMed    
    
    
    
97. WU J, Wang W, Gao L, Shao X, et al
    Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Cancer. 2024 Mar 14. doi: 10.1002/cncr.35270.
    PubMed     Abstract available
    
    
    
98. PUKLIN LS, Ferrucci LM, Harrigan M, McGowan C, et al
    Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35280.
    PubMed     Abstract available
    
    
    
99. ZHENG Q, Yan H, He Y, Wang J, et al
    An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35248.
    PubMed     Abstract available
    
    
    February 2024
100. HOU X, Li X, Han Y, Xu H, et al
     Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
     Cancer. 2024 Feb 29. doi: 10.1002/cncr.35261.
     PubMed     Abstract available
     
     
     
101. LI X, Luo S, Fu W, Huang M, et al
     Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
     Cancer. 2024 Feb 15. doi: 10.1002/cncr.35228.
     PubMed     Abstract available
     
     
     
102. NGUYEN SM, Tran HTT, Long J, Shrubsole MJ, et al
     Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer.
     Cancer. 2024 Feb 6. doi: 10.1002/cncr.35229.
     PubMed     Abstract available
     
     
     January 2024
103. XIONG W, Xu T, Liu X, Zhang L, et al
     Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
     Cancer. 2024 Jan 25. doi: 10.1002/cncr.35206.
     PubMed     Abstract available
     
     
     
104. QU F, Lu R, Liu Q, Wu X, et al
     Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
     Cancer. 2024 Jan 25. doi: 10.1002/cncr.35205.
     PubMed     Abstract available
     
     
     
105. SMITH KL, Zhao F, Mayer IA, Tevaarwerk AJ, et al
     Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
     Cancer. 2024 Jan 18. doi: 10.1002/cncr.35187.
     PubMed     Abstract available
     
     
     
106. WANG J, Xia YC, Tian BX, Li JT, et al
     Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
     Cancer. 2024 Jan 13. doi: 10.1002/cncr.35176.
     PubMed     Abstract available
     
     
     
107. ZHOU X, Liu M, Zheng Z, Cao X, et al
     Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population-based study.
     Cancer. 2024 Jan 10. doi: 10.1002/cncr.35166.
     PubMed     Abstract available
     
     
     
108. LIANG X, Zhang L, Gui X, Di L, et al
     Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.
     Cancer. 2024 Jan 10. doi: 10.1002/cncr.35174.
     PubMed     Abstract available
     
     
     
109. AGGARWAL A, Han L, Lewis D, Costigan J, et al
     Association of travel time, patient characteristics, and hospital quality with patient mobility for breast cancer surgery: A national population-based study.
     Cancer. 2024 Jan 8. doi: 10.1002/cncr.35153.
     PubMed     Abstract available
     
     
     
110. SATHISHKUMAR K, Sankarapillai J, Mathew A, Nair RA, et al
     Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme.
     Cancer. 2024 Jan 6. doi: 10.1002/cncr.35188.
     PubMed     Abstract available
     
     
     
111. BHATT R, van den Hout A, Antoniou AC, Shah M, et al
     Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors.
     Cancer. 2024 Jan 4. doi: 10.1002/cncr.35183.
     PubMed     Abstract available
     
     
     December 2023
112. AKKOC MUSTAFAYEV FN, Shukla MA, Lanier A, Milton DR, et al
     Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
     Cancer. 2023 Dec 15. doi: 10.1002/cncr.35159.
     PubMed     Abstract available
     
     
     
113. ZHANG S, Guo L, Zhang Z, Liu X, et al
     Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
     Cancer. 2023 Dec 11. doi: 10.1002/cncr.35142.
     PubMed     Abstract available
     
     
     November 2023
114. WILLIAMS AD, Ruth K, Shaikh SS, Vasigh M, et al
     Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
     Cancer. 2023 Nov 29. doi: 10.1002/cncr.35136.
     PubMed     Abstract available
     
     
     
115. YU T, Lu Y, Fang J, Jiang X, et al
     Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
     Cancer. 2023 Nov 11. doi: 10.1002/cncr.35096.
     PubMed     Abstract available
     
     
     
116. LI J, Jiang Z
     Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects.
     Cancer. 2023 Nov 3. doi: 10.1002/cncr.35093.
     PubMed     Abstract available
     
     
     
117. ZHU J, Wang L, Gong W, Li X, et al
     Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study.
     Cancer. 2023 Nov 2. doi: 10.1002/cncr.35095.
     PubMed     Abstract available
     
     
     July 2023
118. GEFFEN SR, Poteat T, Dean LT, Malone J, et al
     Engaging black sexual minority women in breast cancer research: Lessons in community partnerships.
     Cancer. 2023 Jul 25. doi: 10.1002/cncr.34960.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.